SCHEMBL22925691

SCHEMBL22925691

N=C(NO)c1ccc(Nc2ncc(-c3ccc(C(F)(F)F)cc3)o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 9/20 0.51
▸ VCP P55072 5/20 0.49
▸ FLT1 P17948 3/20 0.47
▸ KDR P35968 3/20 0.47
▸ FLT4 P35916 2/20 0.47
▸ ALOX5 P09917 1/20 0.43
▸ GSK3B P49841 1/20 0.41
▸ PRKAB2 O43741 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ PRKAG1 P54619 1/20 0.41
▸ PRKAA2 P54646 1/20 0.41
▸ PRKAA1 Q13131 1/20 0.41
▸ RPS6KA1 Q15418 1/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.41
▸ PRKAG3 Q9UGI9 1/20 0.41
▸ PRKAG2 Q9UGJ0 1/20 0.41
▸ PRKAB1 Q9Y478 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29696323 0.87 TRPV1 (0.48) TRPV1VCPFLT1KDRFLT4
SCHEMBL22925497 0.87 TRPV1 (0.48) TRPV1VCPFLT1KDRFLT4
SCHEMBL28733672 0.87 TRPV1 (0.50) TRPV1VCPFLT1KDRFLT4
SCHEMBL28939277 0.86 TRPV1 (0.51) TRPV1VCPFLT1KDRFLT4
SCHEMBL23540014 0.84 VCP (0.69) TRPV1VCPFLT1KDRFLT4
SCHEMBL26307279 0.81 FLT1 (0.52) TRPV1VCPFLT1KDRFLT4
SCHEMBL23540651 0.81 VCP (0.69) TRPV1VCPFLT1KDRFLT4
SCHEMBL28733704 0.81 TRPV1 (0.48) TRPV1VCPFLT1KDRFLT4
SCHEMBL24637017 0.80 TRPV1 (0.48) TRPV1VCPFLT1KDRFLT4
SCHEMBL22925553 0.80 TRPV1 (0.49) TRPV1VCPFLT1KDRFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 — — US disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB TRPV1 4690/4885VCP 595/4885FLT1 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback